A randomized phase 2 study of the triplet combination of ridaforolimus (RIDA), dalotuzumab (DALO) and exemestane (EX) compared to the ridaforolimus, exemestane doublet in high proliferation, estrogen receptor positive (ER+) advanced breast cancer Meeting Abstract
| Authors: | Rugo, H. S.; Tredan, O.; Ro, J.; Morales, S. M.; Musolina, A.; Afonso, N.; Ferreira, M.; Park, K. H.; Cortes, J.; Tan, A. R.; Blum, J. L.; Eaton, L.; Mauro, D.; Gause, C.; Im, E.; Baselga, J. |
| Abstract Title: | A randomized phase 2 study of the triplet combination of ridaforolimus (RIDA), dalotuzumab (DALO) and exemestane (EX) compared to the ridaforolimus, exemestane doublet in high proliferation, estrogen receptor positive (ER+) advanced breast cancer |
| Meeting Title: | 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 73 |
| Issue: | 24 Suppl. |
| Meeting Dates: | 2013 Dec 10-14 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2013-12-15 |
| Language: | English |
| ACCESSION: | WOS:000209496900077 |
| DOI: | 10.1158/0008-5472.sabcs13-ot2-6-13 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: OT2-6-13 -- Source: Wos |
